AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

Air NZ to airports: Stop subsidising Jetstar
Markets

Air NZ to airports: Stop subsidising Jetstar

Current airport regulation works against the national interest, Air NZ’s new CEO says.

Genesis sets out gas strategy
Markets

Genesis sets out gas strategy

Storage, Kupe’s long-term role and LNG flexibility anchor the plan.

Ports owned by councils ‘underperform’ – is it time to list?
Markets

Ports owned by councils ‘underperform’ – is it time to list?

There is clear evidence that listing leads to better businesses, market experts say.

RBNZ data scotches Dosh claims of bank registration application
Finance

RBNZ data scotches Dosh claims of bank registration application

The regulator received no bank-registration applications in July 2024.